		\mathcal{C}	
	Application No.	Applicant(s)	
Mating of Allews Lills	10/659,928	MAKIUCHI ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Maureen M. Wallenhorst	1743	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to the response received on July 30, 2004.			
2. The allowed claim(s) is/are <u>2-4 (renumbered 1-3)</u> .			
3. The drawings filed on 11 September 2003 are accepted by the Examiner.			
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some* c) ☒ None of the:			
1. Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this national stage application from the			
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.			
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 			
Attachment(s)			
1. Notice of References Cited (PTO-892)		tent Application (PTO-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary (Paper No./Mail Date	PTO-413),	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date), 7. Examiner's Amendm	ent/Comment	
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Statemer	nt of Reasons for Allowance	
of Biological Material	9. Other	2. Academs for Allowance	

Application/Control Number: 10/659,928

Art Unit: 1743

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sylvia Tan on September 16, 2004.

Claim 2 was rewritten as follows:

- --Claim 2: A method of measuring a blood component in a control serum using a dry analytical process comprising the steps of: applying a control serum to a dry analytical element containing reagents for reacting with the blood component, and measuring the reaction between the reagents and the blood component, wherein said control serum is prepared from fibrin-free or fibrin-removed serum without performing dialysis, followed by freezing or freeze-drying, and further wherein said blood component is selected from the group consisting of blood urea nitrogen, uric acid, total cholesterol, creatinine, albumin, high density lipoprotein cholesterol, magnesium, alkaline phosphatase, and creatine kinase subunit MB. —
- 2. The following is an examiner's statement of reasons for allowance: Application serial no. 10/659,928 is being allowed since none of the prior art of record teaches or fairly suggests a method for measuring a blood component in a control serum using a dry analytical process, wherein the control serum is prepared from a serum from which fibrin has been removed but which has not been subjected to dialysis, followed by freezing or freeze-drying.

Application/Control Number: 10/659,928

Art Unit: 1743

Any comments considered necessary by applicant must be submitted no later than the

Page 3

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication or earlier communications from the 3.

examiner should be directed to Maureen M. Wallenhorst whose telephone number is 571-272-

1266. The examiner can normally be reached on Monday-Wednesday from 6:30 AM to 4:00

PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jill Warden, can be reached on 571-272-1267. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maureen M. Wallenhorst Primary Examiner

Art Unit 1743

mmw

September 20, 2004

Mainter M. Walleshorst MAUREEN M. WALLENHORST PRIMARY EXAMINER

GROUP (SEE LOOD